Peer-reviewed photobiomodulation (PBM) research published between 2023 and early 2026 continues to strengthen the science behind application areas that matter most to commercial operators: mitochondrial mechanism, wavelength effects in skin fibroblasts, pre-exercise muscle recovery, and safety in older adults.
This digest covers five high-quality publications. Each entry explains what was studied, what researchers found, and what operators can reasonably take from the findings for programming and member education.
What Does the Research Say About How PBM Actually Works at the Cellular Level?
A widely cited review by Michael R. Hamblin published in Photochemistry and Photobiology remains the most comprehensive synthesis of PBM cellular mechanisms and continues to anchor how researchers frame new studies.
Hamblin identified cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain, as the primary chromophore absorbing red and near-infrared photons in mammalian cells. CCO, which can be inhibited by nitric oxide under physiological stress conditions, absorbs photons in the 600 to 900 nm range. This absorption displaces the inhibitory nitric oxide, restoring electron transport, increasing mitochondrial membrane potential, and driving adenosine triphosphate (ATP) synthesis. Downstream, reactive oxygen species activate transcription factors, producing anti-inflammatory and pro-proliferative gene expression changes.
Two practical points emerge from this framework. Cells under metabolic stress respond more robustly to PBM than optimally functioning cells, which helps explain why recovery applications tend to show stronger effect sizes than baseline performance enhancement. The review also documented biphasic dose responses: lower fluences produced peak ATP gains, while higher fluences produced diminishing or reversed effects. Power density and total fluence both matter.
For operators, remember that this is the scientific framework that peer-reviewed research applies to the mechanism, not a vendor claim about any specific device.
Does Wavelength Selection Matter for Skin Biology?
For operators whose clients ask about wavelength differences, a 2023 study published in Oxidative Medicine and Cellular Longevity provides granular in vitro evidence on how specific wavelengths affect skin fibroblast biology.
Baldassarro, Alastra, Lorenzini, Giardino, and Calza exposed human fibroblasts to six LED wavelengths: 440, 525, 645, 660, 780, and 900 nm at a fixed irradiance of 0.1 mW/cm², tracking mitochondrial membrane potential, reactive oxygen species production, and cell death. The 645 nm wavelength with a single exposure protocol produced the most pronounced mitochondrial membrane potential increase while minimizing cell death relative to higher energy visible wavelengths. Red-range LED preconditioning also protected fibroblasts against subsequent oxidative stress, suggesting the PBM exposure conferred cellular resilience rather than just an acute energy boost.
For operators, red wavelengths in the 630 to 660 nm range have a documented effect on skin fibroblast mitochondrial activity in vitro, while blue light at 440 nm produced more cytotoxic effects at the same irradiance. Wavelength selection is not interchangeable.
What Does a Comprehensive Skin PBM Review Say About Dermatological Applications?
The 2024 review "Unlocking the Power of Light on the Skin," published in the International Journal of Molecular Sciences by Naharro-Rodriguez, Fernandez-Guarino, Hernandez-Bule, and Bacci, surveyed PBM and LED phototherapy literature from the prior six years with a dermatological focus.
The review found consistent evidence that PBM using red and near-infrared wavelengths accelerates wound healing, reduces oxidative stress markers in fibroblasts and keratinocytes, supports collagen production, and produces minimal adverse effects at therapeutic irradiances. Research is expanding into photoaging, skin clarity, dyspigmentation, and post-procedure recovery, with wound healing showing some of the most robust evidence. The authors flagged that parameter standardization remains a challenge; irradiance, wavelength, pulse mode, and session duration vary widely across published protocols, limiting direct comparisons.
For operators, this review characterizes the skin biology research landscape as active and broadly supportive of red and near-infrared PBM. Operators citing it in member education should present the findings as promising, with the appropriate note that protocol variation means outcomes are not uniformly predictable across all device types.
Pre-Exercise PBM and Muscle Endurance: What Does a 2024 Meta-Analysis Find?
A 2024 meta-analysis published in Lasers in Medical Science by Li, Qiu, Ni, and colleagues examined whether PBM applied before physical activity improves muscle endurance and recovery from exercise-induced muscle damage.
The analysis pooled randomized controlled trial data across activity levels, evaluating pre-exercise PBM on muscle endurance outcomes (repetitions, time to exhaustion) and post-exercise damage markers including creatine kinase (CK) and delayed-onset muscle soreness (DOMS). Pre-exercise PBM was associated with statistically significant improvements in endurance and reductions in creatine kinase in the post-exercise window across both laser and LED delivery systems.
Effect sizes were more pronounced in untrained and recreationally active participants than in elite athletes, consistent with the mechanistic finding that PBM produces larger cellular energy benefits in tissues operating closer to their metabolic limits.
For operators, the meta-analysis population profile aligns well with a typical commercial wellness clientele. The findings support programming PBM before workouts for members focused on endurance and reduced soreness. Attribution stays with the research, not with any specific device.
How Does PBM Compare to Other Recovery Modalities?
A 2025 systematic review and meta-analysis in the Journal of Bodywork and Movement Therapies by Canez, da Silva, Ferreira, de Araujo, and Luza compared PBM against neuromuscular electrical stimulation (NMES) and intermittent pneumatic compression (IPC) across 19 randomized clinical trials involving 672 participants.
The central finding showed there is low-certainty evidence that PBM applied before exercise significantly reduces muscle soreness. Both NMES and IPC applied after exercise showed no significant soreness reduction versus control in this specific pool. PBM was the only modality in the comparison to reach statistical significance on the primary soreness outcome, though the authors flagged that protocol variability limits firm conclusions.
For operators, this is a direct comparator study. The research does not endorse any specific device. It indicates that pre-exercise PBM has a stronger evidence signal for soreness reduction than post-exercise compression or electrical stimulation in the pooled RCT data. When members ask how PBM compares to compression boots or NMES devices, this published comparison is a useful reference.
What Does the Research Say About PBM Safety and Tolerability in Older Adults?
A 2024 systematic review in Biomedicines by Godaert and Drame examined PBM efficacy and safety in adults aged 60 and over, searching the literature through February 2024 and identifying 10 studies across four domains: neurodegenerative conditions, wound healing, macular degeneration, and hyposalivation.
The most operationally relevant finding showed that all included studies reported good compliance and safety throughout treatment, with no serious adverse events attributable to PBM documented across the reviewed trials. Efficacy results were mixed by application area, as wound healing and macular degeneration showed more consistent positive findings than cognitive outcomes. The reviewers concluded that PBM appears to be a promising complementary treatment in older adults, while noting that parameter harmonization is needed before best-practice protocols can be established.
For operators, the absence of serious adverse events supports running PBM programs with older adult members. The protocol variability issue the authors flagged reinforces the importance of using a well-characterized device and following consistent session parameters.
Study-at-a-Glance: Key Findings for Operators
|
Author(s) & Year |
Focus |
Key Finding |
Operator Implication |
|
Hamblin MR (2018) |
PBM mechanism (CCO) |
CCO is the primary photon absorber; nitric oxide displacement restores transport; biphasic dose response confirmed |
Irradiance and fluence are not arbitrary; dose-response matters |
|
Baldassarro et al. (2023) |
Wavelength effects in fibroblasts |
645 nm maximized membrane potential; red preconditioning protected cells; blue (440 nm) was more cytotoxic |
Wavelength selection is biologically meaningful; red/NIR is the appropriate range |
|
Naharro-Rodriguez (2024) |
PBM and dermatology |
Consistent evidence for wound healing and collagen support; parameter gaps remain |
Cite findings as promising; note variability across protocols |
|
Li et al. (2024) |
Pre-exercise PBM |
Reduced CK levels and improved endurance, especially in recreationally active adults |
Supports pre-session programming for active adult clients |
|
Canez et al. (2025) |
PBM vs. NMES vs. IPC |
PBM was the only modality reaching statistical significance for soreness reduction |
PBM holds a favorable position in the published comparator literature |
|
Godaert & Drame (2024) |
PBM in older adults |
Good compliance and safety across all studies; no serious adverse events |
Supports operating PBM programs with 60+ populations |
Frequently Asked Questions: Operators on PBM Research
When clients ask "Is this scientifically proven?" what is the honest answer?
PBM has a substantial peer-reviewed literature, with systematic reviews and meta-analyses supporting specific outcomes in muscle recovery and wound healing in RCT populations. The research characterizes PBM as a promising and well-tolerated modality with the strongest evidence in recovery, and an expanding but more heterogeneous evidence base in other fields. Overstatement in either direction is not accurate.
What should I tell clients about whole-body PBM vs. targeted clinical laser therapy?
Most PBM research uses targeted lasers or localized LED arrays. Whole-body bed systems deliver a different exposure geometry, meaning more surface area and lower localized intensity per site. Do not directly transpose findings from targeted clinical laser applications to whole-body exposures. The mechanistic pathway is the same, but dose geometry and clinical populations differ.
How do I know if the PBM device I operate delivers parameters consistent with published research?
The key parameters are wavelength (nm), irradiance (mW/cm²), fluence (J/cm²), session duration, and treatment frequency. A device with documented 65 mW/cm² irradiance at red and near-infrared wavelengths with 10 to 20 minute sessions sits within ranges appearing across the published literature, though variability across studies means no single parameter set is universally correct.
What do "low-certainty evidence" GRADE ratings mean in practice?
Low certainty means the direction of effect is consistent (PBM reduces soreness, improves healing) but exact effect size confidence is limited by heterogeneity across studies. It does not mean ineffective. It means the science is building toward the protocol standardization needed for high-certainty conclusions.
Are there safety concerns from the research?
The reviewed literature consistently reports good tolerability at therapeutic irradiances. Parameters to monitor include power density (excessive irradiance can cause thermal effects), eye exposure (protection is standard), and contraindications including active malignancy and photosensitizing medications. No serious adverse events were documented in the studies reviewed here.
Citations
-
Hamblin MR. Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. Photochem Photobiol. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5844808/
-
Baldassarro VA, Alastra G, Lorenzini L, Giardino L, Calza L. Photobiomodulation at Defined Wavelengths Regulates Mitochondrial Membrane Potential and Redox Balance in Skin Fibroblasts. Oxid Med Cell Longev. 2023. https://pubmed.ncbi.nlm.nih.gov/37663921/
-
Naharro-Rodriguez J, Fernandez-Guarino M, Hernandez-Bule ML, Bacci S. Unlocking the Power of Light on the Skin: A Comprehensive Review on Photobiomodulation. Int J Mol Sci. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11049838/
-
Godaert L, Drame M. Efficacy of Photobiomodulation Therapy in Older Adults: A Systematic Review. Biomedicines. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11274037/
-
Hamblin MR, Zein R, Selting W. Review of light parameters and photobiomodulation efficacy. J Biomed Opt. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC8355782/
Related Resources
-
Red Light Therapy Wavelength Guide: Deep Tissue vs. Surface Depth
-
Why Body Balance System Is FDA Registered: What It Means for Operators
A Note on OvationULT and Research Attribution
Findings in this digest are attributed to the broad scientific research landscape, not to the OvationULT or any specific Body Balance System product. The OvationULT delivers 65 mW/cm² irradiance in standard 10 to 20 minute sessions and is backed by a five-year warranty. Body Balance System is an FDA-registered manufacturer, and the OvationULT carries FDA Registration number 3010627475 under the ILY product code as a Class II medical device. Operators should use clinical research to educate members, not to guarantee individual outcomes.